. 2022 Mar 2;11(5):1369. doi: 10.3390/jcm11051369

Table 4.

Multivariate Cox regression analyses for patient overall survival.

		Tumour Size < 5 cm		Tumour Size ≥ 5 cm
		Multivariate Cox Analysis		Multivariate Cox Analysis
		HR (95% CI)	p-Value	HR (95% CI)	p-Value
AR		0.54 (0.37–0.77)	0.001	0.84 (0.53–1.32)	0.439
Age (years)	50–60 years	0.88 (0.57–1.34)	0.540	0.73 (0.49–1.08)	0.115
Age (years)	>60 years	1.28 (0.79–2.09)	0.319	0.84 (0.54–1.29)	0.421
Sex	Female	0.77 (0.49–1.21)	0.251	0.78 (0.52–1.16)	0.219
Primary disease	HCV	1.35 (0.74–2.45)	0.322	1.59 (0.75–3.37)	0.227
Primary disease	NBNC	0.91 (0.51–1.62)	0.746	0.90 (0.58–1.41)	0.642
Preoperative TACE	Yes	1.43 (0.96–2.11)	0.076	1.20 (0.83–1.73)	0.332
AFP (ng/mL)	100–1000	1.36 (0.90–2.06)	0.147	0.96 (0.62–1.50)	0.856
AFP (ng/mL)	>1000	1.39 (0.86–2.24)	0.180	1.07 (0.71–1.61)	0.735
Platelet	≥150	0.78 (0.53–1.14)	0.190	0.74 (0.54–1.02)	0.07
Log-transformed AST		1.88 (1.29–2.76)	0.001	1.24 (0.90–1.69)	0.185
Total bilirubin	≥1.5	1.29 (0.73–2.30)	0.382	1.73 (0.99–3.01)	0.053
Albumin		0.62 (0.39–0.99)	0.044	0.81 (0.55–1.19)	0.276
PT (INR)		0.96 (0.80–1.15)	0.636	0.61 (0.08–4.70)	0.632
ICG R15	≥15	1.06 (0.72–1.56)	0.774	1.20 (0.83–1.72)	0.337
Number of tumours	Multiple	2.23 (1.46–3.41)	<0.001	2.25 (1.54–3.28)	<0.001
Macrovascular invasion		2.00 (0.72–5.60)	0.186	1.13 (0.61–2.07)	0.7
Microvascular invasion		1.61 (0.62–4.15)	0.327	1.77 (0.98–3.20)	0.058
Edmondson–Steiner grade	III–IV	1.57 (1.11–2.21)	0.011	1.26 (0.88–1.79)	0.203

AFP, alpha-fetoprotein; AST, aspartate aminotransferase; AR, anatomic resection; CI, confidence interval; HCV, hepatitis C virus; HR, hazard ratio; ICG R15, indocyanine green retention rate at 15 min; INR, international normalised ratio; NBNC, non-HBV non-hepatitis C virus; PT, prothrombin time; TACE, transcatheter arterial chemoembolisation.